Clinical Approach to Easy Bruising and Bleeding
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of easy bruising and bleeding
Easy bruising and abnormal bleeding are among the most common reasons for hematology referrals, accounting for approximately 15-20% of outpatient consultations. Studies indicate that up to 12% of healthy women report easy bruising, and the prevalence increases significantly with age, affecting up to 25% of individuals over 65 years. While the majority of cases represent benign conditions or normal variants, approximately 10-15% of patients with significant bleeding symptoms will have an underlying bleeding disorder requiring specific management.
Definitions
Easy bruising (ecchymosis): The appearance of subcutaneous hemorrhages (bruises) with minimal or no apparent trauma, or bruises that are disproportionately large relative to the inciting injury.
Bleeding tendency: A predisposition to prolonged or excessive bleeding from minor injuries, surgical procedures, or spontaneous bleeding without identifiable trauma. This reflects an underlying defect in hemostasis—the physiological process that stops bleeding while maintaining normal blood flow.
Classification by Duration
| Category | Duration | Common Causes | Clinical Significance |
|---|---|---|---|
| Acute | Less than 2 weeks | Drug-induced thrombocytopenia, acute infections (viral), disseminated intravascular coagulation, trauma | Often requires urgent evaluation; may indicate serious underlying condition |
| Subacute | 2 weeks to 3 months | New medication effects, evolving bone marrow disorders, nutritional deficiencies | Progressive worsening warrants prompt investigation |
| Chronic/Lifelong | Greater than 3 months or since childhood | Inherited bleeding disorders (von Willebrand disease, hemophilia), chronic liver disease, chronic immune thrombocytopenia | Suggests inherited disorder if present since childhood; acquired causes if adult onset |
Classification by Bleeding Pattern
Mucocutaneous Bleeding (Primary Hemostasis Defects)
Characteristic features: Petechiae, superficial ecchymoses, epistaxis, gingival bleeding, menorrhagia, gastrointestinal bleeding, prolonged bleeding from cuts
Suggests: Platelet disorders (quantitative or qualitative) or vascular abnormalities
Timing: Immediate bleeding after injury
Deep Tissue Bleeding (Secondary Hemostasis Defects)
Characteristic features: Hemarthroses (joint bleeding), deep muscle hematomas, retroperitoneal bleeding, delayed surgical bleeding
Suggests: Coagulation factor deficiencies (hemophilia A or B, acquired factor inhibitors)
Timing: Delayed bleeding hours after initial hemostasis
Classification by Site and Pattern
| Bleeding Site/Pattern | Description | Most Likely Category |
|---|---|---|
| Petechiae | Pinpoint (less than 2 mm) non-blanching red spots | Thrombocytopenia or platelet dysfunction |
| Purpura | Larger (3 mm to 1 cm) non-blanching purple lesions | Thrombocytopenia, vasculitis, or vascular fragility |
| Ecchymoses | Large bruises (greater than 1 cm) in subcutaneous tissue | May occur in any bleeding disorder; location matters |
| Hemarthrosis | Bleeding into joint spaces causing pain and swelling | Severe coagulation factor deficiency (hemophilia) |
| Recurrent epistaxis | Frequent nosebleeds, especially bilateral or posterior | von Willebrand disease, platelet disorders, hereditary hemorrhagic telangiectasia |
| Menorrhagia | Heavy menstrual bleeding (greater than 80 mL per cycle or lasting greater than 7 days) | von Willebrand disease (affects up to 20% of women with menorrhagia) |
Classification by Severity
| Severity | Clinical Features | Examples |
|---|---|---|
| Mild | Bleeding only with significant hemostatic challenges (major surgery, severe trauma) | Mild von Willebrand disease, mild hemophilia (factor level 5-40%) |
| Moderate | Bleeding with minor procedures or moderate trauma; occasional spontaneous bleeding | Moderate hemophilia (factor level 1-5%), moderate platelet disorders |
| Severe | Spontaneous bleeding without apparent cause; life-threatening hemorrhage risk | Severe hemophilia (factor level less than 1%), severe thrombocytopenia (less than 10,000/µL) |
Key Concept — The Hemostatic Triad: Normal hemostasis requires three intact components: (1) adequate platelet number and function, (2) intact coagulation factor cascade, and (3) normal vascular integrity. Bleeding symptoms arise when one or more of these components is defective. The pattern of bleeding helps identify which component is affected:
- Platelet or vascular defects: Mucocutaneous bleeding (skin, mucous membranes)
- Coagulation factor defects: Deep tissue bleeding (joints, muscles)
- Combined defects: Both patterns present (disseminated intravascular coagulation, severe liver disease)
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of hemostasis and bleeding disorders
Hemostasis is the complex physiological process that prevents blood loss following vascular injury while maintaining normal blood fluidity. It involves a carefully orchestrated sequence of events: vascular constriction, platelet plug formation (primary hemostasis), fibrin clot stabilization (secondary hemostasis), and eventual clot dissolution (fibrinolysis). Understanding these mechanisms is essential for identifying the cause of bleeding symptoms and guiding appropriate treatment.
The Hemostatic Response: Sequential Phases
| Phase | Key Components | Function | Clinical Correlate |
|---|---|---|---|
| Vascular Phase | Vascular smooth muscle, endothelium | Immediate vasoconstriction reduces blood flow to injured area | Defects cause vascular-type bleeding (hereditary hemorrhagic telangiectasia, scurvy) |
| Primary Hemostasis | Platelets, von Willebrand factor, collagen | Formation of initial platelet plug within seconds to minutes | Defects cause mucocutaneous bleeding (thrombocytopenia, von Willebrand disease) |
| Secondary Hemostasis | Coagulation factors (I-XIII), thrombin | Fibrin mesh reinforces and stabilizes platelet plug over minutes to hours | Defects cause deep tissue bleeding (hemophilia, factor deficiencies) |
| Fibrinolysis | Plasminogen, tissue plasminogen activator, plasmin | Controlled clot dissolution to restore vessel patency | Excessive fibrinolysis causes rebleeding; defective fibrinolysis causes thrombosis |
Primary Hemostasis: Platelet Plug Formation
Adhesion
Process: Platelets adhere to exposed subendothelial collagen at injury site
Key mediators: von Willebrand factor (vWF), glycoprotein Ib-IX-V receptor
Clinical relevance: Defects in vWF or GP Ib cause impaired adhesion (von Willebrand disease, Bernard-Soulier syndrome)
Activation
Process: Platelets change shape, release granule contents (ADP, thromboxane A2)
Key mediators: Thrombin, collagen, ADP, thromboxane A2
Clinical relevance: Aspirin and nonsteroidal anti-inflammatory drugs inhibit thromboxane synthesis; storage pool disorders impair granule release
Aggregation
Process: Platelets bind to each other forming initial hemostatic plug
Key mediators: Fibrinogen, glycoprotein IIb/IIIa receptor
Clinical relevance: GP IIb/IIIa defects cause Glanzmann thrombasthenia; clopidogrel and GP IIb/IIIa inhibitors impair aggregation
Secondary Hemostasis: The Coagulation Cascade
Modern Cell-Based Model of Coagulation: The traditional “waterfall” model has been replaced by a cell-based model with three overlapping phases:
- Initiation: Tissue factor-bearing cells activate factor VII, generating small amounts of thrombin
- Amplification: Thrombin activates platelets and factors V, VIII, and XI on platelet surface
- Propagation: Large-scale thrombin generation on activated platelet surface leads to fibrin formation
| Pathway | Factors Involved | Laboratory Test | Clinical Conditions |
|---|---|---|---|
| Extrinsic Pathway | Tissue factor, Factor VII | Prothrombin time (PT) / International normalized ratio (INR) | Warfarin therapy, vitamin K deficiency, liver disease, factor VII deficiency |
| Intrinsic Pathway | Factors XII, XI, IX, VIII | Activated partial thromboplastin time (aPTT) | Hemophilia A (factor VIII), Hemophilia B (factor IX), factor XI deficiency, heparin therapy |
| Common Pathway | Factors X, V, II (prothrombin), I (fibrinogen) | Both PT and aPTT prolonged | Factor X, V, or II deficiency; severe liver disease; disseminated intravascular coagulation |
| Fibrin Stabilization | Factor XIII | Clot solubility test, factor XIII activity assay | Factor XIII deficiency (delayed bleeding, poor wound healing, umbilical stump bleeding) |
How Specific Conditions Cause Bleeding
| Condition | Mechanism | Treatment Implication |
|---|---|---|
| von Willebrand Disease | Deficiency or dysfunction of von Willebrand factor impairs platelet adhesion to injured vessel wall and reduces factor VIII levels (vWF is carrier protein for factor VIII) | Desmopressin (DDAVP) releases stored vWF; vWF concentrates for severe cases; avoid aspirin |
| Hemophilia A | Deficiency of factor VIII impairs intrinsic pathway amplification, preventing adequate thrombin generation for stable fibrin clot | Factor VIII replacement (recombinant or plasma-derived); emicizumab (bispecific antibody mimicking factor VIII function) |
| Hemophilia B | Deficiency of factor IX impairs intrinsic pathway; similar mechanism to hemophilia A | Factor IX replacement; extended half-life products available |
| Immune Thrombocytopenia (ITP) | Autoantibodies against platelet surface glycoproteins lead to accelerated platelet destruction in spleen and impaired platelet production | Corticosteroids, intravenous immunoglobulin, thrombopoietin receptor agonists, rituximab, splenectomy |
| Liver Disease | Reduced synthesis of clotting factors (II, V, VII, IX, X), reduced thrombopoietin production (thrombocytopenia), portal hypertension (hypersplenism), and impaired clearance of fibrinolytic proteins | Fresh frozen plasma, vitamin K (if cholestatic), platelet transfusion; factor concentrates avoid volume overload |
| Vitamin K Deficiency | Vitamin K is essential cofactor for gamma-carboxylation of factors II, VII, IX, X, and proteins C and S; deficiency produces dysfunctional factors | Vitamin K replacement (oral or parenteral); onset of effect 6-24 hours |
| Disseminated Intravascular Coagulation (DIC) | Systemic activation of coagulation leads to widespread microvascular thrombosis consuming platelets and clotting factors; secondary fibrinolysis causes bleeding | Treat underlying cause; supportive transfusion of platelets, fresh frozen plasma, cryoprecipitate |
| Drug-Induced Platelet Dysfunction | Aspirin irreversibly acetylates cyclooxygenase-1, blocking thromboxane A2 synthesis for platelet lifespan (7-10 days); clopidogrel irreversibly blocks P2Y12 ADP receptor | Drug discontinuation; platelet transfusion if severe bleeding (limited efficacy with circulating drug) |
Vascular Integrity and Bleeding
Structural Vascular Defects
Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu): Abnormal vessel development due to mutations in endoglin or ALK1 genes; arteriovenous malformations in skin, mucosa, and visceral organs
Ehlers-Danlos syndrome: Collagen defects cause vessel fragility; type IV (vascular type) has highest bleeding risk
Marfan syndrome: Fibrillin defects affect vessel wall integrity
Acquired Vascular Defects
Senile purpura: Age-related loss of dermal collagen and subcutaneous fat leads to inadequate vessel support; bruising on extensor surfaces of forearms and hands
Scurvy (vitamin C deficiency): Impaired collagen synthesis leads to perifollicular hemorrhages, corkscrew hairs, and gingival bleeding
Corticosteroid use: Chronic use causes skin atrophy and capillary fragility
Often Overlooked Mechanism: Acquired von Willebrand Syndrome
This underdiagnosed condition occurs secondary to other diseases and causes mucocutaneous bleeding in patients without prior bleeding history. Common associations include:
- Cardiovascular: Aortic stenosis (high shear stress cleaves vWF multimers), ventricular assist devices
- Hematologic: Monoclonal gammopathies, lymphoproliferative disorders, myeloproliferative neoplasms
- Autoimmune: Systemic lupus erythematosus, hypothyroidism
- Medications: Valproic acid, ciprofloxacin, hydroxyethyl starch
Consider acquired von Willebrand syndrome in any adult with new-onset mucocutaneous bleeding and one of these associated conditions.
Factor XIII Deficiency: The “Hidden” Bleeding Disorder
Factor XIII cross-links fibrin and stabilizes clots. Deficiency is not detected by routine PT or aPTT testing. Suspect factor XIII deficiency when:
- Delayed bleeding occurs hours to days after surgery or trauma
- Umbilical stump bleeding in neonates (occurs in approximately 80% of affected newborns)
- Poor wound healing and abnormal scar formation
- Recurrent miscarriage in affected women
- Intracranial hemorrhage (high incidence in untreated patients)
3. History Taking
A comprehensive approach to eliciting the bleeding and bruising history
Red Flags — Require Urgent Evaluation
- Active uncontrolled bleeding — Hemorrhagic emergency
- Signs of intracranial hemorrhage — Severe headache, altered consciousness, focal deficits
- Hemodynamic instability — Tachycardia, hypotension, pallor
- Rapidly progressive petechiae or purpura — Possible disseminated intravascular coagulation or thrombotic thrombocytopenic purpura
- Fever with petechiae — Rule out meningococcemia, endocarditis
- New bleeding in patient on anticoagulation — Risk of major hemorrhage
- Spontaneous hemarthrosis — Suggests severe coagulation factor deficiency
- Unexplained weight loss with bleeding — Consider underlying malignancy or bone marrow disorder
Systematic History: The “BLEEDING” Approach
Use the mnemonic “BLEEDING” to ensure comprehensive history taking:
- B — Bruise characteristics: Size, location, number, relation to trauma, color evolution
- L — Lifelong or recent onset: Present since childhood suggests inherited disorder; adult onset suggests acquired cause
- E — Episodes and triggers: Spontaneous versus provoked bleeding; response to hemostatic challenges (surgery, dental work, trauma, childbirth)
- E — Extent of bleeding: Duration (how long does bleeding last?), volume (transfusion history), sites involved
- D — Drugs and diet: Anticoagulants, antiplatelets, NSAIDs, supplements, alcohol intake, nutritional status
- I — Inherited history: Family history of bleeding disorders, consanguinity, affected relatives
- N — New symptoms: Associated symptoms suggesting underlying disease (fatigue, infections, bone pain, weight loss)
- G — Gynecologic/Gender-specific: Menstrual history (menorrhagia), postpartum hemorrhage, bleeding with shaving
Quantifying Bleeding Severity: Standardized Assessment
The ISTH Bleeding Assessment Tool (BAT)
The International Society on Thrombosis and Haemostasis developed a standardized questionnaire that assigns scores to bleeding symptoms at different sites. Key thresholds suggesting a bleeding disorder:
- Adult males: Score ≥4 is abnormal
- Adult females: Score ≥6 is abnormal (higher threshold accounts for menstrual bleeding)
- Children: Score ≥3 is abnormal
A normal bleeding score has high negative predictive value (greater than 99%) for excluding significant bleeding disorders.
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| von Willebrand Disease | Mucocutaneous bleeding, menorrhagia, family history, lifelong symptoms | “Have you ever needed treatment to stop a nosebleed? Do you soak through a pad or tampon every hour during your period?” |
| Hemophilia | Joint and muscle bleeding, male predominance, family history (X-linked) | “Have you ever had swelling and pain in your joints without injury? Did any male relatives have bleeding problems?” |
| Platelet Disorder | Petechiae, immediate bleeding from cuts, gum bleeding | “Do you notice small red dots on your skin? Does bleeding start immediately when you cut yourself?” |
| Drug-Induced | Temporal relationship to medication initiation, improvement with discontinuation | “When did you start any new medications? Have you taken aspirin, ibuprofen, or any blood thinners recently?” |
| Liver Disease | Alcohol history, viral hepatitis risk factors, stigmata of chronic liver disease | “How much alcohol do you drink? Have you ever been told you have liver problems or hepatitis?” |
| Bone Marrow Disorder | Pancytopenia symptoms (bleeding, infections, fatigue), B symptoms | “Have you had frequent infections or unexplained fevers? Do you feel more tired than usual?” |
| Vitamin K Deficiency | Malabsorption, prolonged antibiotic use, dietary deficiency | “Have you had any problems with your digestion or absorbing food? Have you been on antibiotics for a long time?” |
| Connective Tissue Disorder | Joint hypermobility, easy scarring, skin hyperextensibility, family history | “Are you unusually flexible? Do your wounds heal slowly or leave unusual scars?” |
| Factitious/Non-Accidental | Unusual locations, inconsistent history, secondary gain, unexplained patterns | “Can you show me exactly where the bruises are? How did each one happen?” (Document carefully; consider social assessment) |
Hemostatic Challenge History: Critical Questions
| Challenge | Normal Response | Abnormal Response (Suggests Bleeding Disorder) |
|---|---|---|
| Dental extraction | Bleeding stops within 30-60 minutes; no rebleeding | Prolonged bleeding (greater than 24 hours), rebleeding, need for packing or cautery, blood transfusion |
| Surgery | Hemostasis achieved intraoperatively; no excessive drain output | Unexpected surgical bleeding, hematoma formation, return to operating room, transfusion requirement |
| Childbirth | Blood loss less than 500 mL (vaginal) or less than 1000 mL (cesarean) | Postpartum hemorrhage requiring intervention, transfusion, prolonged lochia |
| Minor cuts | Bleeding stops within 5-10 minutes with pressure | Bleeding for more than 15 minutes despite pressure, need for medical attention |
| Menstruation | 3-7 days duration, less than 80 mL total blood loss | Duration greater than 7 days, changing pad/tampon hourly, clots larger than a quarter, iron deficiency anemia |
Medication and Social History
Medications That Cause Bleeding
- Anticoagulants: Warfarin, heparin, direct oral anticoagulants (apixaban, rivaroxaban, dabigatran, edoxaban)
- Antiplatelet agents: Aspirin, clopidogrel, prasugrel, ticagrelor, dipyridamole
- NSAIDs: Ibuprofen, naproxen, diclofenac (reversible platelet inhibition)
- SSRIs: Selective serotonin reuptake inhibitors impair platelet serotonin uptake
- Antibiotics: Prolonged use depletes vitamin K-producing gut flora
- Supplements: Fish oil, vitamin E, ginkgo biloba, garlic, ginger (high doses)
- Chemotherapy: Myelosuppressive agents cause thrombocytopenia
- Valproic acid: Causes thrombocytopenia and acquired von Willebrand syndrome
Social and Dietary History
- Alcohol use: Chronic use causes liver disease, thrombocytopenia, and nutritional deficiencies
- Diet: Assess for vitamin K intake (green leafy vegetables), vitamin C deficiency risk, malnutrition
- Occupation: Trauma risk, chemical exposures (benzene and bone marrow suppression)
- Exercise: Contact sports increase bleeding risk in undiagnosed disorders
- Recent illness: Viral infections can trigger immune thrombocytopenia
- Pregnancy status: Gestational thrombocytopenia, HELLP syndrome consideration
Family History Details
- Bleeding disorders in relatives (specify relationship)
- Consanguinity (increases autosomal recessive disorder risk)
- Deaths from bleeding or postoperative complications
- Pattern of inheritance (X-linked, autosomal dominant/recessive)
4. Physical Examination
A systematic head-to-toe approach for easy bruising and bleeding
Systematic Framework: The examination of a patient with bleeding or bruising should accomplish three goals: (1) identify active bleeding sites, (2) characterize the type and distribution of bleeding manifestations, and (3) detect signs of underlying systemic disease. Use the “Head to Extremities” approach combined with careful skin survey.
General Inspection
- Overall appearance: Pallor (suggesting chronic blood loss or anemia), cachexia (malignancy), cushingoid features (steroid use)
- Skin survey: Systematically examine all skin surfaces including back, buttocks, and scalp for bruising patterns
- Level of consciousness: Confusion or altered mental status may indicate intracranial hemorrhage or severe anemia
- Signs of distress: Pain from hemarthrosis or deep hematoma, respiratory distress from pulmonary hemorrhage
- Body habitus: Marfanoid features, joint hypermobility suggesting connective tissue disorder
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Heart Rate | Tachycardia (greater than 100 beats per minute), orthostatic increase | Compensatory response to blood loss; orthostatic tachycardia suggests 15-30% volume loss |
| Blood Pressure | Hypotension, orthostatic drop (greater than 20 mmHg systolic) | Late sign of hemorrhage; orthostatic hypotension suggests significant volume depletion |
| Respiratory Rate | Tachypnea | Compensatory for anemia or metabolic acidosis from shock |
| Temperature | Fever | Suggests infection (with thrombocytopenia consider sepsis, meningococcemia); also seen in malignancy |
| Oxygen Saturation | Hypoxemia | Severe anemia, pulmonary hemorrhage, or pulmonary embolism (in hypercoagulable disorders) |
Skin Examination: The Key to Pattern Recognition
| Finding | Description | Associated Conditions |
|---|---|---|
| Petechiae | Pinpoint (less than 2 mm) non-blanching red macules; do not fade with pressure | Thrombocytopenia (most common), platelet dysfunction, vasculitis, fat embolism |
| Purpura | Larger non-blanching purple lesions (3 mm to 1 cm); may be flat (non-palpable) or raised (palpable) | Non-palpable: thrombocytopenia, vascular fragility; Palpable: vasculitis |
| Ecchymoses | Large bruises (greater than 1 cm); note location, size, age (color evolution from red to blue to green to yellow) | Location matters: dependent areas (normal aging), trauma sites, or unusual locations (trunk, face suggest pathology) |
| Telangiectasias | Small dilated blood vessels visible on skin or mucous membranes; blanch with pressure | Hereditary hemorrhagic telangiectasia (lips, tongue, fingers), liver disease (spider angiomata) |
| Perifollicular hemorrhages | Hemorrhages around hair follicles with corkscrew hairs | Scurvy (vitamin C deficiency) |
| Palpable purpura | Raised purpuric lesions, may be tender | Leukocytoclastic vasculitis, Henoch-Schönlein purpura, cryoglobulinemia |
| Senile purpura | Dark purple ecchymoses on extensor forearms and dorsal hands; atrophic skin | Age-related dermal atrophy, chronic sun exposure, corticosteroid use |
Head and Neck Examination
Eyes
- Conjunctival pallor: Indicates anemia from blood loss
- Subconjunctival hemorrhage: Common in thrombocytopenia; also seen with Valsalva, hypertension
- Scleral icterus: Suggests liver disease or hemolysis
- Fundoscopy: Retinal hemorrhages (thrombocytopenia, leukemia, severe anemia, hypertensive emergency)
Oral Cavity
- Gingival bleeding or hypertrophy: Spontaneous gum bleeding suggests severe thrombocytopenia; gingival hypertrophy in acute leukemia
- Mucosal petechiae: Buccal mucosa, palate — look for blood blisters (wet purpura, indicates higher bleeding risk)
- Telangiectasias: Lips and tongue in hereditary hemorrhagic telangiectasia
- Glossitis: Smooth tongue suggests nutritional deficiency (B12, folate, iron)
Neck
- Lymphadenopathy: May suggest lymphoproliferative disorder, infection
- Thyroid: Goiter or thyroid nodules (hypothyroidism associated with acquired von Willebrand syndrome)
Cardiovascular Examination
- Heart sounds: Ejection systolic murmur of aortic stenosis (associated with acquired von Willebrand syndrome — Heyde syndrome)
- Flow murmur: High-output state from severe anemia
- Signs of heart failure: May indicate cardiac involvement in amyloidosis (also causes factor X deficiency)
- Mechanical heart valve: Patient likely on anticoagulation
Abdominal Examination
- Hepatomegaly: Liver disease, malignancy, congestive hepatopathy
- Splenomegaly: Hypersplenism causing thrombocytopenia; myeloproliferative neoplasms; portal hypertension
- Ascites: Advanced liver disease, malignancy
- Stigmata of chronic liver disease: Caput medusae, spider angiomata (upper body), palmar erythema, gynecomastia, testicular atrophy
- Abdominal wall hematoma: May occur with anticoagulation, can be palpable or cause flank discoloration (Grey Turner sign in retroperitoneal hemorrhage)
Musculoskeletal Examination
- Joint swelling: Hemarthrosis causes warm, swollen, painful joint with limited range of motion; most common in knees, elbows, ankles in hemophilia
- Chronic arthropathy: Joint deformity and muscle atrophy from recurrent hemarthroses
- Muscle hematomas: Palpable tender masses in muscle compartments; check for compartment syndrome signs
- Joint hypermobility: Beighton score assessment for Ehlers-Danlos syndrome and hypermobility spectrum disorders
Extremities
- Digital ischemia: May indicate vasculitis, cryoglobulinemia, disseminated intravascular coagulation
- Nail bed hemorrhages: Splinter hemorrhages (endocarditis, vasculitis)
- Telangiectasias: Finger pulps in hereditary hemorrhagic telangiectasia
- Skin texture: Velvety, hyperextensible skin in Ehlers-Danlos syndrome
- Peripheral edema: Liver disease, nephrotic syndrome, heart failure
Neurological Examination
- Mental status: Confusion may indicate intracranial hemorrhage or severe anemia
- Focal deficits: Suggest intracranial bleeding — urgent neuroimaging required
- Signs of raised intracranial pressure: Papilledema, Cushing response (hypertension and bradycardia)
- Peripheral neuropathy: May indicate amyloidosis, vitamin deficiency, or paraneoplastic syndrome
Expected Findings by Etiology
| Condition | Skin Findings | Other Key Findings | Red Flags |
|---|---|---|---|
| Immune Thrombocytopenia | Petechiae, ecchymoses, mucosal bleeding | Often otherwise normal examination; no splenomegaly (distinguishes from hypersplenism) | Wet purpura (oral blood blisters) indicates high bleeding risk |
| von Willebrand Disease | Mucocutaneous bleeding, bruising | Usually normal examination; may have evidence of prior epistaxis or menorrhagia | Often overlooked due to normal physical examination |
| Hemophilia | Deep tissue hematomas, often spares skin | Joint swelling, chronic arthropathy, muscle hematomas | Compartment syndrome, pseudotumor (expanding hematoma) |
| Liver Disease | Spider angiomata, easy bruising, ecchymoses | Jaundice, hepatosplenomegaly, ascites, gynecomastia, palmar erythema | Variceal bleeding, hepatic encephalopathy |
| Leukemia/Bone Marrow Failure | Petechiae, ecchymoses, pallor | Lymphadenopathy, hepatosplenomegaly, fever, gingival hypertrophy (acute myeloid leukemia) | Pancytopenia manifestations: bleeding, infection, severe anemia |
| Disseminated Intravascular Coagulation | Petechiae, purpura, bleeding from multiple sites, acral cyanosis | Signs of underlying cause (sepsis, malignancy); digital ischemia | Rapidly progressive, multiorgan involvement |
| Senile/Corticosteroid Purpura | Dark ecchymoses on dorsal forearms and hands; thin atrophic skin | Other signs of aging or steroid use (skin fragility, poor wound healing) | Usually benign; rule out other causes if atypical distribution |
| Hereditary Hemorrhagic Telangiectasia | Multiple telangiectasias on lips, tongue, face, fingers | Epistaxis history; may have hepatic or pulmonary arteriovenous malformations | Stroke or brain abscess from pulmonary AVM (right-to-left shunt) |
Important Teaching Point
Normal physical examination is common! Many bleeding disorders present with completely normal physical examination findings between bleeding episodes. In particular:
- von Willebrand disease: The most common inherited bleeding disorder often has no examination abnormalities
- Mild hemophilia: May have no findings until hemostatic challenge
- Mild platelet function disorders: Often normal between bleeding episodes
- Factor XIII deficiency: No examination findings; normal coagulation tests
A normal examination does NOT exclude a significant bleeding disorder. The history remains the most important diagnostic tool.
5. Differential Diagnosis
Systematic approach organized by probability and clinical features
Diagnostic Framework: Organize the differential diagnosis by asking three key questions:
- What is the bleeding pattern? Mucocutaneous (platelet/vascular) versus deep tissue (coagulation factor)
- Is this inherited or acquired? Lifelong history versus recent onset
- What is the underlying mechanism? Decreased production, increased destruction, dysfunction, or consumption
Mucocutaneous Bleeding Pattern (Primary Hemostasis Defects)
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON (approximately 70%) | Drug-induced platelet dysfunction | History of aspirin, NSAIDs, clopidogrel use; temporal relationship | Concurrent anticoagulation increases risk |
| von Willebrand Disease | Lifelong mucocutaneous bleeding, menorrhagia, family history; most common inherited bleeding disorder (prevalence approximately 1%) | Often undiagnosed; may present first with surgical bleeding | |
| Immune Thrombocytopenia (ITP) | Isolated thrombocytopenia, often follows viral illness; petechiae, wet purpura | Platelet count less than 10,000/µL; intracranial hemorrhage risk | |
| LESS COMMON (approximately 20%) | Liver Disease | Stigmata of chronic liver disease, hepatosplenomegaly; combined platelet and coagulation defects | Variceal bleeding, hepatic encephalopathy |
| Bone Marrow Disorders | Pancytopenia symptoms (bleeding, infections, fatigue); may have lymphadenopathy, splenomegaly | Leukemia blasts, severe pancytopenia | |
| Drug-induced Thrombocytopenia | Temporal relationship to new medication; common culprits: heparin, quinine, sulfonamides, vancomycin | Heparin-induced thrombocytopenia: paradoxical thrombosis | |
| UNCOMMON BUT SERIOUS (approximately 10%) | Thrombotic Thrombocytopenic Purpura (TTP) | Pentad: thrombocytopenia, microangiopathic hemolytic anemia, neurologic symptoms, fever, renal impairment | Medical emergency; do NOT transfuse platelets |
| Disseminated Intravascular Coagulation (DIC) | Underlying trigger (sepsis, malignancy, trauma); bleeding AND thrombosis; prolonged PT and aPTT | Rapidly progressive; high mortality | |
| Inherited Platelet Disorders | Lifelong bleeding history, family history; includes Bernard-Soulier syndrome, Glanzmann thrombasthenia | May have severe bleeding with normal platelet count |
Deep Tissue Bleeding Pattern (Secondary Hemostasis Defects)
| Probability | Condition | Key Features | Red Flags |
|---|---|---|---|
| COMMON | Anticoagulant Therapy | Patient on warfarin, heparin, or direct oral anticoagulants; supratherapeutic levels | INR greater than 4; active bleeding; need for urgent reversal |
| Vitamin K Deficiency | Malabsorption, prolonged antibiotics, malnutrition, cholestatic liver disease | Prolonged PT with normal aPTT initially; responds to vitamin K | |
| LESS COMMON | Hemophilia A (Factor VIII Deficiency) | Male patient, lifelong history, joint and muscle bleeding, X-linked family history | Spontaneous hemarthrosis, intracranial hemorrhage |
| Hemophilia B (Factor IX Deficiency) | Clinically indistinguishable from hemophilia A; requires factor assay for differentiation | Same as hemophilia A | |
| Acquired Factor Inhibitors | New-onset severe bleeding in older adult; often autoimmune; acquired hemophilia A most common | aPTT does not correct with mixing study; can be life-threatening | |
| UNCOMMON | Factor XI Deficiency | Variable bleeding severity; more common in Ashkenazi Jewish population; bleeding usually with surgery/trauma | Prolonged aPTT; factor level does not predict bleeding severity |
| Factor XIII Deficiency | Delayed bleeding, umbilical stump bleeding, poor wound healing; normal PT and aPTT | High risk of intracranial hemorrhage; easily missed | |
| Rare Factor Deficiencies (II, V, VII, X) | Autosomal recessive; consanguinity increases risk; severity varies by factor and level | Factor VII deficiency: isolated prolonged PT |
Step-by-Step Diagnostic Approach
Systematic Approach to Bleeding/Bruising:
- Step 1: Rule out medication-related causes — Review all prescription drugs, over-the-counter medications, and supplements
- Step 2: Classify by bleeding pattern — Mucocutaneous suggests platelet/vascular defect; deep tissue suggests coagulation factor defect
- Step 3: Determine chronicity — Lifelong history suggests inherited disorder; recent onset suggests acquired cause
- Step 4: Order baseline coagulation studies — Complete blood count, PT/INR, aPTT, fibrinogen
- Step 5: Use results to guide further testing — See investigation algorithm in Task 6
Mechanistic Approach: Where Is the Defect?
Platelet Disorders
Quantitative:
Immune thrombocytopenia
Drug-induced thrombocytopenia
Bone marrow failure/infiltration
Hypersplenism
Qualitative:
Drug-induced dysfunction
Uremia
Inherited disorders (Glanzmann, Bernard-Soulier)
Coagulation Factor Disorders
Inherited:
Hemophilia A and B
von Willebrand disease
Rare factor deficiencies
Acquired:
Vitamin K deficiency
Liver disease
Anticoagulant therapy
Acquired inhibitors
Vascular Disorders
Inherited:
Hereditary hemorrhagic telangiectasia
Ehlers-Danlos syndrome
Marfan syndrome
Acquired:
Senile purpura
Scurvy (vitamin C deficiency)
Corticosteroid-induced
Vasculitis
Combined/Complex Disorders
Consumption:
Disseminated intravascular coagulation
Thrombotic microangiopathies
Multiple defects:
Liver disease
Massive transfusion
Cardiopulmonary bypass
Drug-Induced Bleeding: Comprehensive Reference
| Drug or Drug Class | Mechanism | Characteristics | Time to Resolution After Stopping |
|---|---|---|---|
| Aspirin | Irreversible COX-1 inhibition; blocks thromboxane A2 synthesis | Mucocutaneous bleeding; prolongs bleeding time; normal platelet count | 7-10 days (platelet lifespan) |
| Clopidogrel, Prasugrel, Ticagrelor | P2Y12 ADP receptor inhibition (irreversible for clopidogrel/prasugrel) | Mucocutaneous bleeding; high surgical bleeding risk | 5-7 days (clopidogrel/prasugrel); 3-5 days (ticagrelor) |
| NSAIDs (non-aspirin) | Reversible COX inhibition | Milder platelet dysfunction than aspirin | 24-72 hours (varies by half-life) |
| Warfarin | Vitamin K antagonist; reduces factors II, VII, IX, X | Deep tissue and mucocutaneous bleeding; prolonged PT/INR | 3-5 days; reversible with vitamin K or factor replacement |
| Heparin (unfractionated) | Potentiates antithrombin; inhibits thrombin and factor Xa | Prolonged aPTT; also causes HIT (heparin-induced thrombocytopenia) | 4-6 hours; protamine reversal available |
| Low molecular weight heparin | Primarily anti-Xa activity via antithrombin | Less aPTT prolongation; monitor anti-Xa levels | 12-24 hours; partial protamine reversal |
| Direct oral anticoagulants (DOACs) | Direct thrombin inhibition (dabigatran) or factor Xa inhibition (rivaroxaban, apixaban, edoxaban) | May have normal or mildly abnormal PT/aPTT; specific assays needed | 24-48 hours; specific reversal agents available |
| SSRIs | Inhibit platelet serotonin uptake; impair platelet aggregation | Increased bleeding risk especially with concurrent NSAID/anticoagulant use | 1-2 weeks |
| Valproic acid | Thrombocytopenia; acquired von Willebrand syndrome; platelet dysfunction | Dose-dependent; may cause multiple hemostatic defects | Days to weeks after discontinuation |
| Chemotherapy agents | Bone marrow suppression causing thrombocytopenia | Nadir typically 7-14 days after treatment; severity varies by regimen | Recovery typically 21-28 days; varies by agent |
| Fish oil (high dose) | Inhibits platelet aggregation; alters membrane composition | Usually clinically insignificant at standard doses | Days |
| Antibiotics (prolonged use) | Reduced vitamin K synthesis by gut flora; some have direct effects | Prolonged PT; often subclinical unless other risk factors present | Days to weeks; vitamin K responsive |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Petechiae + low platelets + otherwise well | Immune thrombocytopenia | Peripheral smear; rule out secondary causes |
| Petechiae + fever + ill-appearing | Sepsis, meningococcemia, DIC | Blood cultures, DIC panel, urgent antibiotics |
| Mucocutaneous bleeding + normal platelet count | von Willebrand disease, platelet function disorder | von Willebrand panel, platelet function studies |
| Hemarthrosis in male patient | Hemophilia A or B | Factor VIII and IX assays |
| Prolonged aPTT only, PT normal | Heparin, factor VIII/IX/XI deficiency, lupus anticoagulant | Mixing study, factor assays, lupus anticoagulant testing |
| Prolonged PT only, aPTT normal | Warfarin, vitamin K deficiency, factor VII deficiency | Review medications, vitamin K trial, factor VII assay |
| Both PT and aPTT prolonged | Liver disease, DIC, common pathway factor deficiency, supratherapeutic anticoagulation | Liver function tests, DIC panel, mixing study |
| Normal PT, aPTT, platelet count with significant bleeding | von Willebrand disease, factor XIII deficiency, platelet function disorder, vascular disorder | von Willebrand panel, factor XIII activity, platelet function testing |
| Thrombocytopenia + microangiopathic hemolysis + neurologic changes | Thrombotic thrombocytopenic purpura (TTP) | ADAMTS13 activity; urgent plasma exchange |
| Telangiectasias + recurrent epistaxis + family history | Hereditary hemorrhagic telangiectasia | Genetic testing; screen for visceral AVMs |
| Bruising on forearms/hands + elderly + thin skin | Senile purpura | Reassurance if no other bleeding; consider vitamin C status |
| New bleeding + aortic stenosis | Acquired von Willebrand syndrome (Heyde syndrome) | von Willebrand panel including multimer analysis |
6. Diagnostic Investigations
A stepwise, cost-effective approach guided by clinical suspicion
Baseline Investigations for All Patients
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Complete Blood Count (CBC) | Assess platelet count; detect anemia and other cytopenias | Thrombocytopenia (less than 150,000/µL); anemia suggesting blood loss; pancytopenia suggesting marrow pathology | Always review peripheral smear if platelet count abnormal or if pancytopenia present |
| Peripheral Blood Smear | Evaluate platelet morphology; detect schistocytes, abnormal cells | Giant platelets (inherited disorders), schistocytes (microangiopathic hemolysis), blasts (leukemia), platelet clumping (pseudothrombocytopenia) | Essential to rule out pseudothrombocytopenia (EDTA-induced clumping); request citrate tube if suspected |
| Prothrombin Time (PT) / INR | Assess extrinsic and common pathway factors (VII, X, V, II, fibrinogen) | Prolonged in warfarin use, vitamin K deficiency, liver disease, DIC, factor VII deficiency | INR standardized for warfarin monitoring; PT ratio more useful for other conditions |
| Activated Partial Thromboplastin Time (aPTT) | Assess intrinsic and common pathway factors (XII, XI, IX, VIII, X, V, II, fibrinogen) | Prolonged in hemophilia, heparin use, lupus anticoagulant, factor deficiencies | Lupus anticoagulant prolongs aPTT but causes thrombosis, not bleeding |
| Fibrinogen Level | Assess fibrinogen quantity (common pathway end product) | Low in DIC, severe liver disease, dysfibrinogenemia, massive bleeding | Normal range: 200-400 mg/dL; critical if less than 100 mg/dL |
| Thrombin Time (TT) | Assess conversion of fibrinogen to fibrin | Prolonged by heparin, direct thrombin inhibitors, fibrinogen abnormalities, fibrin degradation products | Very sensitive to heparin contamination; useful for detecting dabigatran effect |
Interpreting Coagulation Test Patterns
| PT | aPTT | Platelets | Most Likely Diagnoses |
|---|---|---|---|
| Normal | Normal | Normal | von Willebrand disease, factor XIII deficiency, platelet function disorder, vascular disorder, mild factor deficiency |
| Normal | Normal | Low | Immune thrombocytopenia, drug-induced thrombocytopenia, bone marrow disorder, hypersplenism |
| Normal | Prolonged | Normal | Hemophilia A or B, factor XI deficiency, heparin, lupus anticoagulant, von Willebrand disease (if factor VIII low) |
| Prolonged | Normal | Normal | Early warfarin therapy, early vitamin K deficiency, factor VII deficiency |
| Prolonged | Prolonged | Normal | Warfarin (therapeutic or supratherapeutic), vitamin K deficiency, liver disease, common pathway factor deficiency, supratherapeutic heparin |
| Prolonged | Prolonged | Low | DIC, severe liver disease, massive transfusion, bone marrow failure with coagulopathy |
Targeted Investigations by Suspected Etiology
If Suspecting von Willebrand Disease
First-Line Tests
- von Willebrand Factor Antigen (vWF:Ag): Measures quantity of vWF protein; reduced in types 1 and 3
- von Willebrand Factor Activity (vWF:RCo or vWF:GPIbM): Measures vWF function; reduced in all types
- Factor VIII Activity: Often reduced because vWF carries and stabilizes factor VIII
Second-Line Tests
- vWF Multimer Analysis: Determines vWF multimer distribution; abnormal in type 2 variants
- vWF:CB (Collagen Binding): Assesses vWF function; helps classify type 2
- RIPA (Ristocetin-Induced Platelet Aggregation): Increased sensitivity in type 2B
- Genetic Testing: For confirmation and family screening
Testing Caveats for von Willebrand Disease
vWF levels fluctuate: Elevated by stress, exercise, pregnancy, estrogen, inflammation. May need repeat testing if initially normal but clinical suspicion high. Blood type O individuals have 25-30% lower vWF levels (consider type O-specific reference ranges).
If Suspecting Hemophilia
First-Line Tests
- Factor VIII Activity Assay: Reduced in hemophilia A; severity classified as severe (less than 1%), moderate (1-5%), or mild (5-40%)
- Factor IX Activity Assay: Reduced in hemophilia B; same severity classification
Second-Line Tests
- Mixing Study: If aPTT prolonged; correction suggests factor deficiency; no correction suggests inhibitor
- Inhibitor Screen (Bethesda Assay): Quantifies inhibitor titer if mixing study suggests inhibitor
- Genetic Testing: For confirmation, carrier detection, prenatal diagnosis
If Suspecting Platelet Disorder
First-Line Tests
- Peripheral Blood Smear: Platelet morphology (giant platelets, granule abnormalities)
- Platelet Function Analyzer (PFA-100/200): Screens for platelet dysfunction and von Willebrand disease; closure time prolonged
Second-Line Tests
- Light Transmission Aggregometry (LTA): Gold standard for platelet function; tests response to multiple agonists (ADP, collagen, epinephrine, arachidonic acid, ristocetin)
- Flow Cytometry: Detects surface glycoprotein deficiencies (Bernard-Soulier, Glanzmann)
- Electron Microscopy: For storage pool disorders
If Suspecting DIC
DIC Panel
- D-dimer: Elevated (fibrin degradation product)
- Fibrinogen: Decreased (consumed)
- PT and aPTT: Prolonged
- Platelet Count: Decreased (consumed)
- Peripheral Smear: Schistocytes (microangiopathic hemolysis)
ISTH DIC Scoring System
- Platelet count: greater than 100 (0), 50-100 (1), less than 50 (2)
- D-dimer: No increase (0), moderate increase (2), strong increase (3)
- PT prolongation: less than 3 sec (0), 3-6 sec (1), greater than 6 sec (2)
- Fibrinogen: greater than 100 mg/dL (0), less than 100 mg/dL (1)
- Score ≥5: Compatible with overt DIC
If Suspecting Thrombotic Microangiopathy (TTP/HUS)
| Test | Expected Finding | Interpretation |
|---|---|---|
| ADAMTS13 Activity | Less than 10% in TTP | Severely deficient in TTP; normal or mildly reduced in other TMAs |
| ADAMTS13 Inhibitor | Present in acquired TTP | Distinguishes acquired (inhibitor present) from congenital TTP |
| Peripheral Smear | Schistocytes (greater than 1%) | Microangiopathic hemolytic anemia |
| LDH | Markedly elevated | Reflects hemolysis and tissue ischemia |
| Haptoglobin | Undetectable | Consumed in intravascular hemolysis |
| Direct Coombs Test | Negative | Rules out autoimmune hemolytic anemia |
Special Testing Considerations
Factor XIII Deficiency Testing
Easily Missed Diagnosis
Factor XIII deficiency is NOT detected by PT or aPTT. Suspect this diagnosis when:
- Delayed bleeding (hours to days after surgery or trauma)
- Umbilical stump bleeding at birth
- Poor wound healing or abnormal scarring
- Recurrent miscarriage
- Family history of intracranial hemorrhage
Tests: Clot solubility assay (screening), Factor XIII activity assay (confirmatory). Normal activity is greater than 70%; bleeding risk increases when less than 30%.
Mixing Study Interpretation
| Mixing Study Result | Interpretation | Next Steps |
|---|---|---|
| Corrects immediately and at 2 hours | Factor deficiency | Order specific factor assays based on which test was prolonged |
| Does not correct | Inhibitor present | If aPTT prolonged: test for lupus anticoagulant and factor VIII inhibitor |
| Corrects immediately but prolongs at 2 hours | Time-dependent inhibitor (classic for factor VIII inhibitor) | Bethesda assay to quantify inhibitor titer |
Empiric Treatment Trials as Diagnostic Tools
Therapeutic Trials Can Aid Diagnosis
In certain situations, response to therapy can support a suspected diagnosis:
- Vitamin K Trial: If PT prolonged, give vitamin K 10 mg IV or oral. Correction within 24-48 hours confirms vitamin K deficiency or warfarin effect; no correction suggests liver synthetic failure
- Desmopressin (DDAVP) Trial: In suspected von Willebrand disease type 1, DDAVP challenge with vWF levels before and 1-2 hours after helps confirm diagnosis and assess treatment response
- Platelet Transfusion Response: Post-transfusion platelet increment helps distinguish destruction (poor increment) from production failure (adequate increment)
- Corticosteroid Trial: In suspected immune thrombocytopenia, response to steroids supports the diagnosis (though other causes may also respond)
Testing in Anticoagulated Patients
| Anticoagulant | Effect on PT | Effect on aPTT | Specific Assay |
|---|---|---|---|
| Warfarin | Prolonged (primary monitoring test) | May be mildly prolonged | INR |
| Unfractionated Heparin | May be prolonged at high doses | Prolonged (primary monitoring test) | Anti-Xa level |
| Low Molecular Weight Heparin | Usually normal | May be mildly prolonged | Anti-Xa level (4 hours post-dose) |
| Dabigatran | May be mildly prolonged | Prolonged | Dilute thrombin time, ecarin clotting time |
| Rivaroxaban, Apixaban, Edoxaban | May be prolonged (rivaroxaban > others) | May be mildly prolonged | Anti-Xa level (drug-specific calibration) |
Practical Point: When to Test for Bleeding Disorders
Testing for inherited bleeding disorders (von Willebrand disease, factor deficiencies) should ideally be performed:
- When patient is not acutely bleeding (acute phase response elevates vWF and factor VIII)
- Off anticoagulation when safely possible
- Not during pregnancy or postpartum (pregnancy elevates vWF and factor VIII)
- Not on estrogen-containing contraceptives if von Willebrand disease suspected
- Consider repeat testing if initial results borderline or do not match clinical picture
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Active hemorrhage with hemodynamic instability | EMERGENT | Resuscitation, transfusion, identify bleeding source, reverse anticoagulation if applicable, urgent hematology and surgical consultation |
| Suspected intracranial hemorrhage (severe headache, altered consciousness, focal deficits) | EMERGENT | Emergent CT head, correct coagulopathy immediately, neurosurgical consultation |
| Petechiae with fever and ill appearance | EMERGENT | Blood cultures, empiric antibiotics immediately (meningococcemia until proven otherwise), DIC panel |
| Thrombocytopenia with schistocytes and neurologic changes | EMERGENT | Suspect TTP; do NOT transfuse platelets; send ADAMTS13; urgent plasma exchange consultation |
| Severe thrombocytopenia (less than 10,000/µL) with wet purpura | URGENT | Admit for monitoring, platelet transfusion if bleeding, initiate ITP treatment if confirmed, hematology consultation |
| Acute hemarthrosis in known or suspected hemophilia | URGENT | Factor replacement before imaging; do not wait for lab confirmation if strong suspicion; pain management |
| Supratherapeutic INR (greater than 9) without active bleeding | URGENT | Hold warfarin, vitamin K 5-10 mg orally, recheck INR in 24 hours, assess for occult bleeding |
| Easy bruising with normal initial workup | ROUTINE | Complete history, consider von Willebrand testing, outpatient hematology referral if significant bleeding score |
| Isolated mild thrombocytopenia (100,000-150,000/µL), asymptomatic | ROUTINE | Repeat CBC to confirm, peripheral smear review, outpatient workup for secondary causes |
Step 2: Classify by Bleeding Pattern
Mucocutaneous Pattern
Features: Petechiae, superficial ecchymoses, epistaxis, gingival bleeding, menorrhagia, immediate bleeding from cuts
Suggests: Platelet disorder or vascular defect
Proceed to: Algorithm A
Deep Tissue Pattern
Features: Hemarthrosis, muscle hematomas, retroperitoneal bleeding, delayed surgical bleeding
Suggests: Coagulation factor deficiency
Proceed to: Algorithm B
Step 3: Follow the Appropriate Algorithm
Algorithm A: Mucocutaneous Bleeding Pattern
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Low platelet count + otherwise well + no splenomegaly | Immune thrombocytopenia (ITP) | Peripheral smear to confirm; rule out secondary causes (HIV, HCV, H. pylori, autoimmune); treat based on platelet count and bleeding |
| Low platelet count + splenomegaly | Hypersplenism (liver disease, portal hypertension) | Liver function tests, ultrasound with Doppler; address underlying liver disease |
| Low platelet count + anemia + abnormal cells on smear | Bone marrow disorder (leukemia, MDS, aplastic anemia) | Urgent hematology referral; bone marrow biopsy |
| Low platelet count + schistocytes + elevated LDH | Thrombotic microangiopathy (TTP/HUS) | ADAMTS13, Coombs test; DO NOT transfuse platelets; urgent plasma exchange if TTP suspected |
| Normal platelet count + mucocutaneous bleeding + lifelong history | von Willebrand disease or inherited platelet disorder | von Willebrand panel; if normal, platelet function studies (PFA-100, aggregometry) |
| Normal platelet count + mucocutaneous bleeding + on aspirin/NSAID/antiplatelet | Drug-induced platelet dysfunction | Discontinue offending agent if possible; bleeding should improve in days to 1 week |
| Telangiectasias + recurrent epistaxis + family history | Hereditary hemorrhagic telangiectasia | Clinical diagnosis (Curaçao criteria); screen for pulmonary and hepatic AVMs; genetic testing |
Algorithm B: Deep Tissue Bleeding Pattern
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Prolonged aPTT + normal PT + male + lifelong history | Hemophilia A or B | Factor VIII and IX assays; if low, quantify severity; genetic counseling |
| Prolonged aPTT + normal PT + older adult + new onset | Acquired hemophilia (factor VIII inhibitor) or lupus anticoagulant | Mixing study; if no correction, test for factor VIII inhibitor (Bethesda assay) and lupus anticoagulant |
| Prolonged PT + normal aPTT | Vitamin K deficiency, early warfarin effect, factor VII deficiency | Review medications; vitamin K trial (10 mg); if corrects, vitamin K deficiency confirmed |
| Prolonged PT and aPTT + low fibrinogen + elevated D-dimer | Disseminated intravascular coagulation (DIC) | Identify and treat underlying cause; supportive transfusion (platelets, FFP, cryoprecipitate) |
| Prolonged PT and aPTT + liver disease stigmata | Coagulopathy of liver disease | Liver function tests; manage underlying liver disease; vitamin K trial; transfuse for procedures or bleeding |
| Normal PT and aPTT + deep tissue bleeding + delayed bleeding after surgery | Factor XIII deficiency | Factor XIII activity assay (not detected by routine coagulation tests); clot solubility screening test |
| Patient on anticoagulation + bleeding | Anticoagulant-related bleeding | Check drug levels/INR; hold anticoagulant; specific reversal agent if severe (vitamin K, idarucizumab, andexanet, 4-factor PCC) |
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient needs urgent surgery and has known bleeding disorder | Contact hematology urgently for factor/product replacement plan | Ensure adequate factor levels before and after surgery; may need continuous infusion or repeated dosing |
| Patient on DOAC presents with major bleeding | Hold DOAC; supportive care; specific reversal agent if available (idarucizumab for dabigatran; andexanet alfa for factor Xa inhibitors) | If no specific agent, 4-factor PCC 25-50 units/kg; tranexamic acid as adjunct |
| Patient on warfarin with INR greater than 10 and no bleeding | Hold warfarin; vitamin K 5-10 mg orally | Recheck INR in 24 hours; resume warfarin at lower dose when INR in range |
| Platelet count is 5,000/µL with active mucosal bleeding | Platelet transfusion immediately; IVIg if ITP suspected (faster response than steroids) | Admit for monitoring; initiate ITP treatment; hematology consultation |
| Patient with hemophilia develops joint swelling | Factor replacement FIRST (before imaging or other interventions) | Pain management (avoid NSAIDs); rest, ice, compression, elevation; physiotherapy after acute phase |
| von Willebrand disease patient needs minor procedure | DDAVP trial (if type 1 and known responder); tranexamic acid | If DDAVP insufficient or contraindicated, vWF-containing concentrate |
| Bleeding patient and diagnosis is unclear | Supportive transfusion (packed RBCs for anemia; platelets if less than 50,000 with bleeding; FFP if PT/aPTT greater than 1.5x normal) | Send comprehensive coagulation panel; hematology consultation; avoid blind empiric therapy that may obscure diagnosis |
| Family member asks about testing after relative diagnosed with bleeding disorder | Obtain detailed family history and pedigree | Refer to hematology for appropriate screening based on inheritance pattern (X-linked for hemophilia, autosomal dominant for most vWD) |
When to Refer to Hematology
Urgent Referral
- Suspected TTP or HUS
- Severe thrombocytopenia (less than 20,000/µL)
- Suspected acquired factor inhibitor
- Unexplained DIC
- New diagnosis of hemophilia or severe bleeding disorder
- Life-threatening bleeding of unclear etiology
Routine Referral
- Abnormal bleeding score on standardized assessment
- Suspected von Willebrand disease
- Unexplained easy bruising with normal initial workup
- Family history of bleeding disorder
- Chronic ITP management
- Preoperative evaluation in patient with bleeding history
- Genetic counseling for inherited disorders
Troubleshooting: When Diagnosis Remains Unclear
Ask These Questions
- Is the bleeding history truly abnormal? Use a standardized bleeding assessment tool; many “easy bruisers” have normal hemostasis
- Were samples collected and processed correctly? Hemolyzed or clotted samples give inaccurate results; underfilled citrate tubes falsely prolong PT/aPTT
- Were tests done under optimal conditions? Acute illness, stress, pregnancy, and estrogen can falsely normalize vWF levels
- Was factor XIII tested? This is not detected by PT or aPTT and must be specifically ordered
- Were platelet function studies performed? Normal platelet count does not exclude platelet dysfunction
- Is there more than one defect? Combined disorders (e.g., liver disease) or multiple overlapping causes may exist
- Is this a vascular or connective tissue disorder? These may not show laboratory abnormalities
- Could this be factitious or non-accidental injury? Consider if pattern unusual or history inconsistent
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
History is paramount: The bleeding history is more predictive of surgical bleeding risk than any laboratory test. A detailed, structured bleeding assessment using standardized tools is essential.
Pattern recognition guides testing: Mucocutaneous bleeding suggests platelet or vascular defects; deep tissue bleeding suggests coagulation factor deficiency. Let the pattern guide your workup.
Normal PT and aPTT do not exclude bleeding disorders: von Willebrand disease (most common inherited bleeding disorder), factor XIII deficiency, platelet function disorders, and vascular disorders all have normal routine coagulation tests.
von Willebrand disease is underdiagnosed: Prevalence is approximately 1% but most cases are undiagnosed. Consider testing in any woman with menorrhagia, anyone with mucocutaneous bleeding, and before labeling someone as just an “easy bruiser.”
vWF levels fluctuate: Stress, exercise, pregnancy, inflammation, and estrogen all elevate von Willebrand factor. A single normal result does not exclude the diagnosis if clinical suspicion is high—repeat testing when patient is at baseline.
Blood type matters: Type O individuals have 25-30% lower vWF levels than other blood types. Consider type O-specific reference ranges when interpreting borderline results.
Think factor XIII: When a patient has delayed bleeding (hours to days after surgery), umbilical stump bleeding, or poor wound healing with normal PT and aPTT, order a factor XIII activity level—this diagnosis is easily missed.
Acquired von Willebrand syndrome exists: New-onset mucocutaneous bleeding in adults with aortic stenosis, monoclonal gammopathy, myeloproliferative neoplasms, or on certain medications (valproic acid, LVAD) should prompt vWF testing including multimer analysis.
In TTP, do NOT transfuse platelets: Platelet transfusion can worsen thrombosis and is contraindicated unless life-threatening bleeding. The treatment is plasma exchange—consult hematology immediately.
Drug-induced causes are common: Always take a thorough medication history including over-the-counter drugs and supplements. Aspirin, NSAIDs, SSRIs, and anticoagulants are frequently implicated.
Critical Pitfalls to Avoid
Assuming normal PT/aPTT excludes bleeding disorder: This misses von Willebrand disease, factor XIII deficiency, platelet dysfunction, and vascular disorders—all of which can cause significant bleeding.
Ignoring pseudothrombocytopenia: Always confirm low platelet count with peripheral smear. EDTA-induced platelet clumping is common and causes falsely low automated counts. Request citrate tube if suspected.
Transfusing platelets in TTP: This is dangerous and can fuel microvascular thrombosis. Low platelets in TTP should be treated with plasma exchange, not platelet transfusion.
Delaying factor replacement in hemophilia: In a patient with known or strongly suspected hemophilia, give factor replacement FIRST, before imaging or other interventions. Do not wait for laboratory confirmation during acute bleeding.
Giving NSAIDs to patients with bleeding disorders: NSAIDs impair platelet function and can precipitate or worsen bleeding. Use acetaminophen for analgesia in patients with bleeding tendencies.
Missing acquired hemophilia: New-onset severe bleeding (often soft tissue or retroperitoneal) in an elderly patient with prolonged aPTT that does not correct on mixing study should prompt urgent testing for factor VIII inhibitor. This is life-threatening.
Attributing all bruising in elderly to “senile purpura”: While senile purpura is common, do not miss underlying bone marrow disease, nutritional deficiency, or medication effect. Evaluate thoroughly if bruising is new, progressive, or in unusual locations.
Forgetting to check for heparin contamination: Prolonged aPTT from a line flushed with heparin is a common laboratory artifact. If unexpected aPTT prolongation, repeat from peripheral stick.
Testing for bleeding disorders during acute illness: Acute phase response elevates vWF and factor VIII, potentially masking deficiency. Test when patient is at baseline, off estrogen, and not pregnant if possible.
Missing intracranial hemorrhage: Severe headache, altered mental status, or focal neurologic signs in a patient with bleeding disorder or on anticoagulation requires emergent head CT. Do not delay imaging to await laboratory results.
Key Takeaways
- Bleeding pattern guides diagnosis: Mucocutaneous bleeding (petechiae, epistaxis, menorrhagia) suggests platelet or vascular defect; deep tissue bleeding (hemarthrosis, muscle hematomas) suggests coagulation factor deficiency
- The history is the most valuable diagnostic tool: Use standardized bleeding assessment tools (ISTH-BAT); hemostatic challenge history (dental work, surgery, childbirth) is particularly informative
- Normal routine coagulation tests do not exclude bleeding disorders: von Willebrand disease, factor XIII deficiency, platelet function disorders, and vascular disorders have normal PT and aPTT
- von Willebrand disease is the most common inherited bleeding disorder: Consider in anyone with significant mucocutaneous bleeding, especially women with menorrhagia; testing may need to be repeated due to vWF level fluctuation
- Always review medication list: Drug-induced bleeding (aspirin, NSAIDs, anticoagulants, SSRIs, supplements) is extremely common and often overlooked
- Peripheral blood smear is essential: Confirms true thrombocytopenia (rules out pseudothrombocytopenia), detects schistocytes (TMA), and identifies blasts or other abnormal cells
- TTP is a medical emergency: Thrombocytopenia + microangiopathic hemolytic anemia + neurologic changes = suspect TTP; do NOT transfuse platelets; initiate plasma exchange urgently
- Factor XIII deficiency is easily missed: Normal PT and aPTT; presents with delayed bleeding, umbilical stump bleeding, poor wound healing; must specifically order factor XIII activity
- Treat first in hemophilia emergencies: Give factor replacement before imaging or other interventions when hemophilia is known or strongly suspected
- When in doubt, consult hematology: Unexplained bleeding, abnormal coagulation results, or suspected inherited disorders warrant specialist evaluation
Quick Reference Algorithm
Systematic Approach to Easy Bruising and Bleeding:
- Assess urgency: Is there active hemorrhage, hemodynamic instability, or signs of serious pathology (petechiae + fever, neurologic changes)?
- Take thorough history: Use the “BLEEDING” mnemonic; quantify with standardized bleeding assessment tool; document hemostatic challenge responses
- Classify bleeding pattern: Mucocutaneous versus deep tissue helps distinguish platelet/vascular defects from coagulation factor deficiencies
- Order baseline investigations: CBC with peripheral smear, PT/INR, aPTT, fibrinogen; review for patterns
- Pursue targeted testing based on clinical picture and initial results: von Willebrand panel, factor assays, platelet function studies, mixing studies as indicated
- Remember the “hidden” disorders: Factor XIII deficiency and mild von Willebrand disease can have normal routine testing—order specific tests if clinical suspicion warrants
- Refer to hematology: For confirmed bleeding disorders, unexplained abnormalities, preoperative planning in high-risk patients, or genetic counseling